TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Weight Efficacy Life-style Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Dietary Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: echographic cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and Causality of Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: parental diabetes-related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Azithromycin Cmax from serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Azithromycin Tmax from serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC72 from serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC24 from serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Azithromycin Cmax in epithelial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Azithromycin Tmax in epithelial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Solicited AEs (Local and Systemic)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with at least 0.1 copy of the therapeutic vector
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FFS at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the composite ICH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of CEM results with histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of CAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of L-FABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Observation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glucose level modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nail plate impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail plate thickness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail bed thickness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail thickness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of respiratory syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety Inventory: State-Trait IDARE
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Image Questionnaire (BSQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensory nerve conduction studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Candidate gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glucocorticoid and mineralocorticoid receptor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Regulatory T-cell profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose of Botulinum Toxin Used to Treat Cervical Dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Dose of Botulinum Toxin Used to Treat Blepharospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from Baseline RIT Parent Fidelity Form (RIT-PFF) Score at 15 weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline Unstructured Imitation Assessment (UIA) Score at 15 weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Early Intervention Parenting Self-Efficacy Scale (EIPSES) Score at 15 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in hematologic parameters (Hgb and Platelets)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient and family caregiver participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: [11C]PBR28 binding in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of ROSE preparations per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Procedure Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adequacy of ROSE sample (0-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood cell nuclear factor kappa B (NFkappaB) activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ovarian androgen secretion in response to HCG stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progression-free survival (PFS) at 10 months
Endpoint domain: Mortality/survival
Primary endpoint: parent-proxy QoL chronic cough specific questionnaire (PC-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 4-hour C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: recurrence of acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aromatase inhibitor adherence (Morisky Medication Adherence Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aromatase inhibitor adherence (MAR-Scale global question)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of MNA-D system
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of RFS
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial Eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in plasma p-cresol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute healthcare utilization composite measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in number of regulatory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Negative Urine Cannabinoid Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global messenger RNA (mRNA) and microRNA (miRNA) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of combined therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scar-reducing properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Major pathological response (MPR)
Endpoint domain: Mortality/survival
Primary endpoint: Global Clinical Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local & systemic safety
Endpoint domain: Adverse events/effects
Primary endpoint: AUCt of Chong Kun Dang Tofacitinib Tablet and XELJANZ 5Mg Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Chong Kun Dang Tofacitinib Tablet and XELJANZ 5Mg Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoelectric activity pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of TRA-8 apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of apoptosis regulatory proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with study outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation of frequency of non-random cytogenetic abnormalities with clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation of frequency of specific genetic alterations with clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Host immunologic response to metastatic melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation of the most prevalent gene copy alteration with risk of progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with barriers to medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Time Adjusted-Area Under the Curve (AUC/Time) for Workload During Cycle Ergometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Event Rate of All Major Clinical Events Pre- and Post-Treatment With UX007
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized Event Rate of Major Hypoglycemia Clinical Events Pre- and Post-Treatment With UX007
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (complete & partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Disease Recurrence At 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug
Endpoint domain: Adverse events/effects
Primary endpoint: quality of life questionnaire for hypertension
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Position of the dichrotic notch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Vascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with undetectable PSA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in inflammatory pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Implants Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction Times (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy (% correct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: d'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with documented low glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ketamine pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-Related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Observed Cure Rate Against Strongyloides Stercoralis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Thrombosis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Percent of Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety composite outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Complication occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in tooth colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Database of patients with primary central nervous system tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in sexual and substance-use-related risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in knowledge of HIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained virologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary excretion of GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Dysfunctional Voiding and Incontinence Score (DVISS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of Revised Urinary Incontinence Scale (RUIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sustained Viral Response (SVR) 12 Weeks After End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Family Accommodation Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived pre-to-post SSI change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUCext
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: λz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t 1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen desaturation (SpO2 < 95%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Biochemical markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic embolism
Endpoint domain: Adverse events/effects
Primary endpoint: Non-esterified fatty acid and triglycerides concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrence rate of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: burden of atrial fibrillation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebral desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FTOE (Fractional Tissue Oxygen Extraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amounts of radioactivity excreted in urine and faeces (% of dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic (PK) of idalopirdine and radioactivity in plasma (Cmax, tmax, AUC, t1/2, oral clearance and apparent volume of distribution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of [14C] BMS-275183
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Health Costs
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Improvement of current survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Distance reached in shuttle walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response Rate (RR) for Acute or Prolonged Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response Rate (RR) for Chronic Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of the first SA-PJI after a primary joint arthroplasty
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of medical events after SA-PJI
Endpoint domain: Adverse events/effects
Primary endpoint: Urethral Opening Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cartilage repair tissue observations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Glucose AUC[0-4h]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serotype-specific antibody persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of metachronous peritoneal metastases
Endpoint domain: Mortality/survival
Primary endpoint: Quick Dash
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of responded patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of severe infection
Endpoint domain: Adverse events/effects
Primary endpoint: Management of chronic hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of Clinically Important and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal alveolar bone height loss and thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: adverse events incidence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Need for inhaled nitric oxide or Extracorporeal membrane oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: diurnal plasma ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline of total score of COVID-19 anxiety inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: nvHAP Incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative biopsy-detectable prostate cancer rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blinding success and acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in electrical brain activity associated with neuroplasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Global Impression Scale - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: early diastolic peak tissue Doppler velocity of septal mitral annulus (Em)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in ejection fraction in response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of narcotic pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first request of pain medication
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of optimal position on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of injuries of bronchi and carina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in neutrophil content of induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bioimpedance analysis data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Serum TTR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-cell Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Change in Amelioration of Ketamine-related Task Activation in Inferior Parietal Lobule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Amelioration of Ketamine-related Task Activation in Middle Frontal Gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Amelioration of Ketamine-related Task Activation in Superior Frontal Gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Periodontal alveolar bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of IEGM recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Device Effects related to the DX functionality
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with maintenance of diagnosis of permanent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Technical difficulty
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Changes in LII (sum of 5 contact point discrepancy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes